Catalyst
Slingshot members are tracking this event:
Arrowhead Pharma (ARWR) to Release Top-Line Results in 2016 From Expanded Part A and Part B of Phase 1 Trial Evaluating ARC-AAT in Liver Disease Associated With a Rare Genetic Disorder Causing Alpha-1 Antitrypsin Deficiency (AATD)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ARWR |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 14, 2016
Occurred Source:
http://files.shareholder.com/downloads/AMDA-2OTJP1/3111606358x0x921174/4a7fa8b8-36e9-4adb-80c1-4191e19409a8/ARWR_News_2016_12_14_General_Releases.pdf
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Top-line Results, Expanded Part A And Part B, Phase 1 Trial Results, Arc-aat, Alpha-1 Antitrypsin Deficiency
